Literature DB >> 31989453

Catastrophic antiphospholipid antibody syndrome as a first manifestation of primary antiphospholipid antibody syndrome in a middle-aged man.

Nazrul Hassan Jafry1, Muhammed Mubarak2, Ejaz Ahmed3, Fazal Akhtar3.   

Abstract

Catastrophic antiphospholipid antibody syndrome (CAPS) is a severe form of antiphospholipid antibody syndrome (APS) that sometimes represents the first manifestation of the later syndrome. The clinical manifestations of CAPS are relatively non-specific. Hence, the diagnosis may be delayed, resulting in high mortality. We herein present a case of a 40-year-old male who presented with rapid-onset renal failure, gangrene of finger and toe tips and hematological abnormalities with no underlying secondary cause for this complication. The symptoms were precipitated by febrile illness of short duration. A provisional diagnosis of CAPS was made and treatment instituted. With timely diagnosis and intervention, both the life of the patient and kidney function were salvaged. A high index of suspicion for CAPS is important as early treatment can be lifesaving.

Entities:  

Keywords:  Antiphospholipid antibodies; CAPS; Gangrene; Renal failure

Mesh:

Substances:

Year:  2020        PMID: 31989453      PMCID: PMC7148402          DOI: 10.1007/s13730-020-00446-0

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  12 in total

1.  The catastrophic antiphospholipid syndrome--Asherson's syndrome.

Authors:  Jean-Charles Piette; Ricard Cervera; Roger A Levy; Eugeny L Nasonov; Douglas A Triplett; Yehuda Shoenfeld
Journal:  Ann Med Interne (Paris)       Date:  2003-09

Review 2.  The catastrophic antiphospholipid syndrome.

Authors:  R A Asherson
Journal:  J Rheumatol       Date:  1992-04       Impact factor: 4.666

3.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

4.  Catastrophic Antiphospholipid Syndrome-Associated Nephropathy in a Systemic Lupus Erythematosus Patient Without Lupus Nephritis.

Authors:  Rajib K Gupta; Eric Liu; Eduardo Bonilla; Hind Elsaid
Journal:  Arthritis Rheumatol       Date:  2019-12-10       Impact factor: 10.995

Review 5.  Catastrophic antiphospholipid syndrome.

Authors:  Setu K Vora; Ronald A Asherson; Doruk Erkan
Journal:  J Intensive Care Med       Date:  2006 May-Jun       Impact factor: 3.510

Review 6.  Catastrophic antiphospholipid syndrome: updated diagnostic algorithms.

Authors:  Doruk Erkan; Gerard Espinosa; Ricard Cervera
Journal:  Autoimmun Rev       Date:  2010-08-07       Impact factor: 9.754

Review 7.  Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse.

Authors:  Silvia Bucciarelli; Doruk Erkan; Gerard Espinosa; Ricard Cervera
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 8.  Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines.

Authors:  R A Asherson; R Cervera; P G de Groot; D Erkan; M C Boffa; J C Piette; M A Khamashta; Y Shoenfeld
Journal:  Lupus       Date:  2003       Impact factor: 2.911

9.  Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS.

Authors:  Maria G Tektonidou; Flora Sotsiou; Haralampos M Moutsopoulos
Journal:  J Rheumatol       Date:  2008-08-01       Impact factor: 4.666

10.  Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry".

Authors:  Ricard Cervera; Silvia Bucciarelli; Miguel A Plasín; José A Gómez-Puerta; Joan Plaza; Guillermo Pons-Estel; Yehuda Shoenfeld; Miguel Ingelmo; Gerard Espinos
Journal:  J Autoimmun       Date:  2009-03-26       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.